高级检索
当前位置: 首页 > 详情页

A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2

文献详情

编号/登记号:
注册时间:
研究开始时间:
研究结束时间:
项目类型:
多中心研究:
招募状态:
试验分期:
研究疾病/适应症:
研究类型:
研究单位: [1]Oncology Hospital, Chinese Academy of Medical Sciences [2]Liaoning Tumor Hospital & Institute [3]Jilin University First Hospital [4]First Affiliated Hospital of China Medical University [5]Peking University People's Hospital [6]Zhejiang Cancer Hospital [7]Henan Cancer Hospital [8]Jiangsu Cancer Institute & Hospital [9]Jilin Provincial Tumor Hospital [10]Sun Yat-sen Memorial Hospital,Sun Yat-sen University [11]Sun Yat-sen University Cancer Prevention and Control Center [12]Guangdong Provincial People's Hospital [13]Qingdao University Hospital [14]Hunan Cancer Hospital [15]Anhui Provincial Hospital [16]The First Affiliated Hospital of Anhui Medical University [17]Anhui Provincial Cancer Hospital [18]Tianjin Cancer Hospital [19]The First Affiliated Hospital of Xi'an Jiaotong University School of Medicine [20]Shandong Cancer Hospital and Institute [21]Qilu Hospital of Shandong University [22]West China Hospital [23]The Fourth Hospital of Hebei Medical University [24]Wuhan Union Hospital, China [25]Tongji Hospital [26]Hubei Cancer Hospital [27]Zhejiang University [28]Cancer Hospital Affiliated to Guangxi Medical University [29]Chongqing University Cancer Hospital [30]Cancer Hospital of Guizhou Province [31]Shanxi Province Cancer Hospital [32]Bethune Hospital of Shanxi Province [33]Linyi Cancer Hospital [34]Yantai Yuhuangding Hospital [35]First Affiliated Hospital of Fujian Medical University [36]The First Affiliated Hospital of Xiamen University [37]Weihai Municipal Hospital [38]The Affiliated Hospital of Xuzhou Medical University [39]Xuzhou Central Hospital [40]Affiliated Hospital of Chengde Medical College [41]Affiliated Hospital of Hebei University [42]The First Affiliated Hospital of Xinxiang Medical College [43]Jinan Central Hospital [44]Zibo Central Hospital [45]Weifang People's Hospital [46]Neijiang Second People's Hospital

研究目的:
This study will compare RC48-ADC to physician choice standard treatment. Participants must have HER2-low breast cancer ,previous use of anthracyclines, and have been treated with one or two systemic chemotherapy regimens following recurrence/metastasis.

资源点击量:15101 今日访问量:2 总访问量:962 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北大学附属医院 技术支持:重庆聚合科技有限公司 地址:保定市莲池区裕华东路212号